These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 15190231)

  • 1. Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease.
    Mesnage V; Houeto JL; Bonnet AM; Clavier I; Arnulf I; Cattelin F; Le Fur G; Damier P; Welter ML; Agid Y
    Clin Neuropharmacol; 2004; 27(3):108-10. PubMed ID: 15190231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurotensin receptor agonists and antagonists for schizophrenia.
    Robertson VB; Wilson MS
    Am J Psychiatry; 2005 Mar; 162(3):634; author reply 635. PubMed ID: 15741502
    [No Abstract]   [Full Text] [Related]  

  • 3. A Phase Ib Randomized Controlled Study to Evaluate the Effectiveness of a Single-Dose of the NR2B Selective N-Methyl-D-Aspartate Antagonist MK-0657 on Levodopa-Induced Dyskinesias and Motor Symptoms in Patients With Parkinson Disease.
    Herring WJ; Assaid C; Budd K; Vargo R; Mazenko RS; Lines C; Ellenbogen A; Verhagen Metman L
    Clin Neuropharmacol; 2017; 40(6):255-260. PubMed ID: 29059133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Central administration of the neurotensin receptor antagonist SR48692 attenuates vacuous chewing movements in a rodent model of tardive dyskinesia.
    McCormick SE; Stoessl AJ
    Neuroscience; 2003; 119(2):547-55. PubMed ID: 12770567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder.
    Meltzer HY; Arvanitis L; Bauer D; Rein W;
    Am J Psychiatry; 2004 Jun; 161(6):975-84. PubMed ID: 15169685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
    Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C
    Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurotensin receptor agonists and antagonists for schizophrenia.
    Richelson E; Fredrickson PA; Boules MM
    Am J Psychiatry; 2005 Mar; 162(3):633-4; author reply 635. PubMed ID: 15741499
    [No Abstract]   [Full Text] [Related]  

  • 8. The combination of oral L-DOPA/rimonabant for effective dyskinesia treatment and cytological preservation in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
    Gutiérrez-Valdez AL; García-Ruiz R; Anaya-Martínez V; Torres-Esquivel C; Espinosa-Villanueva J; Reynoso-Erazo L; Tron-Alvarez R; Aley-Medina P; Sánchez-Betancourt J; Montiel-Flores E; Avila-Costa MR
    Behav Pharmacol; 2013 Dec; 24(8):640-52. PubMed ID: 24196024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SR 48692, a specific neurotensin receptor antagonist, has no effect on oesophageal motility in humans.
    Zerbib F; Piche T; Charles F; Galmiche JP; Bruley des Varannes S
    Aliment Pharmacol Ther; 2004 Apr; 19(8):931-9. PubMed ID: 15080855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease.
    van der Stelt M; Fox SH; Hill M; Crossman AR; Petrosino S; Di Marzo V; Brotchie JM
    FASEB J; 2005 Jul; 19(9):1140-2. PubMed ID: 15894565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuropeptide Receptor Ligands for the Treatment of Schizophrenia: Focus on Neurotensin and Tachykinins.
    Griebel G
    Curr Pharm Des; 2015; 21(26):3807-12. PubMed ID: 26044977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of SR 48692 on neurotensin-induced calcium-activated chloride currents in the Xenopus oocyte expression system: agonist-like activity on the levocabastine-sensitive neurotensin receptor and absence of antagonist effect on the levocabastine insensitive neurotensin receptor.
    Botto JM; Guillemare E; Vincent JP; Mazella J
    Neurosci Lett; 1997 Feb; 223(3):193-6. PubMed ID: 9080465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low dose quetiapine for drug induced dyskinesias in Parkinson's disease: a double blind cross over study.
    Katzenschlager R; Manson AJ; Evans A; Watt H; Lees AJ
    J Neurol Neurosurg Psychiatry; 2004 Feb; 75(2):295-7. PubMed ID: 14742609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of gabapentin on the motor response to levodopa: a double-blind, placebo-controlled, crossover study in patients with complicated Parkinson disease.
    Van Blercom N; Lasa A; Verger K; Masramón X; Sastre VM; Linazasoro G
    Clin Neuropharmacol; 2004; 27(3):124-8. PubMed ID: 15190235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic strategies to prevent motor complications in Parkinson's disease.
    Kieburtz K
    J Neurol; 2008 Aug; 255 Suppl 4():42-5. PubMed ID: 18821085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The nonpeptide neurotensin antagonist, SR 48692, used as a tool to reveal putative neurotensin receptor subtypes.
    Dubuc I; Costentin J; Terranova JP; Barnouin MC; Soubrié P; Le Fur G; Rostène W; Kitabgi P
    Br J Pharmacol; 1994 Jun; 112(2):352-4. PubMed ID: 8075852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study).
    Lewitt PA; Hauser RA; Lu M; Nicholas AP; Weiner W; Coppard N; Leinonen M; Savola JM
    Neurology; 2012 Jul; 79(2):163-9. PubMed ID: 22744665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Neurotensin receptor antagonists and therapeutical perspectives].
    Gully D; Maffrand JP; Soubrié P; Rostène W; Kitabgi P; Le Fur G
    Therapie; 1995; 50(1):5-7. PubMed ID: 7754478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro functional evidence of different neurotensin-receptors modulating the motor response of human colonic muscle strips.
    Croci T; Aureggi G; Guagnini F; Manara L; Gully D; Fur GL; Maffrand JP; Mukenge S; Ferla G; Ferrara P; Chalon P; Vita N
    Br J Pharmacol; 1999 Aug; 127(8):1922-8. PubMed ID: 10482925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of new dopamine-blocking agent (oxiperomide) on drug-induced dyskinesias in Parkinson's disease and spontaneous dyskinesias.
    Bédard P; Parkes JD; Marsden CD
    Br Med J; 1978 Apr; 1(6118):954-6. PubMed ID: 638546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.